Research programme: small molecule therapeutics - BlossomHill Therapeutics
Latest Information Update: 21 Apr 2021
At a glance
- Originator BlossomHill Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Autoimmune disorders; Cancer